Publicité
Publicité

IPHA

IPHA logo

Innate Pharma S.A. ADS

1.79
USD
Sponsorisé
+0.05
+2.87%
09 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

1.80

+0.01
+0.50%

IPHA Rapports sur les bénéfices

Ratio de surprise positive

IPHA a dépassé 0 des 1 dernières estimations.

%

Prochain rapport

Date du prochain rapport
26 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.17M
/
-$0.12
Variation implicite de Q3 25 (Revenue/ EPS)
--
/
--
Variation implicite de Q4 24 (Revenue/ EPS)
--
/
--

Innate Pharma S.A. ADS earnings per share and revenue

On 13 nov. 2025, IPHA reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -0.12 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.98 million, with a --% difference. The market reacted with a -5.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 analystes forecast an EPS of -0.12 USD, with revenue projected to reach 2.17 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
For Q3 2025, Innate Pharma S.A. ADS reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved down -5.21%, changed from $1.92 before the earnings release to $1.82 the day after.
The next earning report is scheduled for 26 mars 2026.
Based on 2 analystes, Innate Pharma S.A. ADS is expected to report EPS of -$0.12 and revenue of $2.17M for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité